Showing results (211-220 of 6,006) with videos related to

Sort By:
Pageof 601
Molecular Cancer Therapeutics|April 14, 2005
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancerXinbo Liao, Siqing Tang, J Brantley Thrasher, et al.
Molecular Cancer Therapeutics|April 14, 2005
Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiationIraimoudi S Ayene, Lance P Ford, Cameron J Koch
Molecular Cancer Therapeutics|April 14, 2005
Resveratrol-induced apoptotic death in human U251 glioma cellsHao Jiang, Lijie Zhang, Jarret Kuo, et al.
Molecular Cancer Therapeutics|April 14, 2005
Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathwaysTakayuki Ikezoe, Yang Yang, Kentaro Bandobashi, et al.
Molecular Cancer Therapeutics|April 14, 2005
Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosisSusan Gillespie, Xu Dong Zhang, Peter Hersey
Molecular Cancer Therapeutics|June 16, 2005
Identification of genes and molecular pathways involved in the progression of premalignant oral epitheliaAbhijit G Banerjee, Indraneel Bhattacharyya, Jamboor K Vishwanatha
Molecular Cancer Therapeutics|May 18, 2005
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapyJason J Christiansen, Sigrid A Rajasekaran, Landon Inge, et al.
Molecular Cancer Therapeutics|May 18, 2005
Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cellsJubilee R Stewart, Catherine A O'Brian
Molecular Cancer Therapeutics|May 18, 2005
Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell deathLori Emert-Sedlak, Sanjeev Shangary, Asaf Rabinovitz, et al.
Molecular Cancer Therapeutics|May 18, 2005
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicityCharles F Albright, Nilsa Graciani, Wei Han, et al.
Pageof 601